SI0882453T1 - Use of APC in combination with an antiplatelet agent for treating thrombotic disorders - Google Patents

Use of APC in combination with an antiplatelet agent for treating thrombotic disorders

Info

Publication number
SI0882453T1
SI0882453T1 SI9830755T SI9830755T SI0882453T1 SI 0882453 T1 SI0882453 T1 SI 0882453T1 SI 9830755 T SI9830755 T SI 9830755T SI 9830755 T SI9830755 T SI 9830755T SI 0882453 T1 SI0882453 T1 SI 0882453T1
Authority
SI
Slovenia
Prior art keywords
thrombotic disorders
apc
combination
treatment
antiplatelet agent
Prior art date
Application number
SI9830755T
Other languages
English (en)
Slovenian (sl)
Inventor
Brian William Grinnell
Joseph Anthony Jakubowski
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of SI0882453T1 publication Critical patent/SI0882453T1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • External Artificial Organs (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SI9830755T 1997-06-05 1998-06-02 Use of APC in combination with an antiplatelet agent for treating thrombotic disorders SI0882453T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4862897P 1997-06-05 1997-06-05
PCT/US1998/011071 WO1998055142A1 (en) 1997-06-05 1998-06-01 Methods for treating thrombotic disorders

Publications (1)

Publication Number Publication Date
SI0882453T1 true SI0882453T1 (en) 2005-06-30

Family

ID=21955575

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9830755T SI0882453T1 (en) 1997-06-05 1998-06-02 Use of APC in combination with an antiplatelet agent for treating thrombotic disorders

Country Status (23)

Country Link
US (1) US6071514A (xx)
EP (1) EP0882453B1 (xx)
JP (1) JP2002502421A (xx)
KR (1) KR20010013413A (xx)
CN (2) CN1265598A (xx)
AT (1) ATE286404T1 (xx)
AU (1) AU741983B2 (xx)
BR (1) BR9809932A (xx)
CA (1) CA2293429A1 (xx)
DE (1) DE69828462T2 (xx)
DK (1) DK0882453T3 (xx)
EA (1) EA199901112A1 (xx)
ES (1) ES2235291T3 (xx)
HU (1) HUP0003964A2 (xx)
ID (1) ID23908A (xx)
NO (1) NO995776L (xx)
PL (1) PL337223A1 (xx)
PT (1) PT882453E (xx)
SI (1) SI0882453T1 (xx)
TR (1) TR199903020T2 (xx)
TW (1) TWI228042B (xx)
WO (1) WO1998055142A1 (xx)
ZA (1) ZA984698B (xx)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000062828A1 (en) * 1996-04-30 2000-10-26 Medtronic, Inc. Autologous fibrin sealant and method for making the same
WO1997040864A1 (en) * 1996-04-30 1997-11-06 Medtronic, Inc. Method for making autologous fibrin sealant
US7247708B2 (en) * 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6693075B1 (en) * 1997-10-23 2004-02-17 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6747003B1 (en) 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6953568B1 (en) * 1998-08-25 2005-10-11 Oklahoma Medical Research Foundation Targeting of molecules to large vessel endothelium using EPCR
EP1093814A1 (en) * 1999-10-22 2001-04-25 Boehringer Ingelheim Pharma KG Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders
DE60144366D1 (de) * 2000-02-04 2011-05-19 Scripps Research Inst Neuroprotektive, antithrombotische und anti-entzündliche anwendungen von aktiviertem protein c
US7812132B2 (en) 2000-04-28 2010-10-12 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US20030056244A1 (en) * 2000-05-02 2003-03-20 Ning Huang Feed additive compositions and methods
US20030211094A1 (en) * 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
US8906894B1 (en) 2000-07-27 2014-12-09 Thomas N. Thomas Methods for preventing and treating thrombotic disorders
WO2002030889A2 (en) * 2000-10-13 2002-04-18 The Trustees Of Columbia University In The City Of New York A method for inhibiting new tissue growth in blood vessels in a patient subjected to blood vessel injury
US6942880B1 (en) 2001-04-09 2005-09-13 Medtronic, Inc. Autologous platelet gel having beneficial geometric shapes and methods of making the same
US7064130B2 (en) * 2001-04-20 2006-06-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of radical-scavenging compounds for treatment and prevention of NO-dependent microcirculation disorders
AU2002327649A1 (en) * 2001-09-19 2003-04-01 Mcmaster University Treatment of sepsis with tafi
US20030073636A1 (en) * 2001-09-19 2003-04-17 Oklahoma Medical Research Foundation Method of treating diabetes
NZ532310A (en) 2001-10-05 2007-02-23 Combinatorx Inc Combinations comprising a tetra-substituted pyrimidopyrimidine and a corticosteroid for the treatment of immunoinflammatory disorders
EP1587838B1 (en) 2003-01-10 2015-04-15 Ablynx N.V. Therapeutic polypeptides, homologues thereof, fragments thereof and their use in modulating platelet-mediated aggregation
US20070142272A1 (en) * 2003-01-24 2007-06-21 Zlokovic Berislav V Neuroprotective activity of activated protein c independent of its anticoagulant activity
TW200517114A (en) 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
US20080305100A1 (en) * 2004-07-23 2008-12-11 Zlokovic Berislav V Activated Protein C Inhibits Undesirable Effects of Plasminogen Activator in the Brain
MX349787B (es) * 2006-04-04 2017-08-11 Kg Acquisition Llc Formas de dosis oral que incluyen un agente antiplaqueta y un inhibidor de ácido.
WO2007127834A2 (en) * 2006-04-26 2007-11-08 Medtronic, Inc. Compositions and methods of preparation thereof
US20080003213A1 (en) * 2006-05-22 2008-01-03 Jan Lessem Methods and compositions for the treatment of diseases or conditions associated with increased C-reactive protein, interleukin-6, or interferon-gamma levels
MX2009011619A (es) 2007-04-27 2010-01-18 Cydex Pharmaceuticals Inc Formulaciones que contienen clopidogrel y eter sulfoalquilico-ciclodextrina y metodos de uso.
CA2737131A1 (en) * 2007-09-19 2009-03-26 Zalicus Inc. Therapeutic regimens for the treatment of immunoinflammatory disorders
JP2011506607A (ja) * 2007-12-17 2011-03-03 ザリカス インコーポレイティッド 免疫炎症性障害の処置のための治療法
DE102007063234A1 (de) * 2007-12-31 2009-07-02 Nowak, Attila, Dipl.-Ing. Schnellere Speicherorganisation
US20100280594A1 (en) * 2009-05-01 2010-11-04 Medi-Solve, Llc Antithrombotic Neurovascular Device Containing a Glycoprotein IIB/IIIA Receptor Inhibitor for The Treatment of Brain Aneurysms and/or Acute Ischemic Stroke, and Methods Related Thereto
WO2010132711A1 (en) 2009-05-13 2010-11-18 Cydex Pharmaceuticals, Inc. Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same
CN108159399B (zh) * 2017-12-29 2020-07-24 华中科技大学同济医学院附属同济医院 一种凝血蛋白酶aPC在防治糖尿病心肌病药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US5516650A (en) * 1985-06-27 1996-05-14 Zymogenetics, Inc. Production of activated protein C
US5084274A (en) * 1987-11-17 1992-01-28 Scripps Clinic And Research Foundation Inhibition of arterial thrombotic occlusion or thromboembolism
US4992373A (en) * 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
JP2739050B2 (ja) * 1988-01-28 1998-04-08 ヘキスト薬品工業株式会社 抗血液凝固剤
US4981952A (en) * 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
IL97312A (en) * 1990-02-23 1999-01-26 Lilly Co Eli A method of generating a polypeptide in an eukaryotic vector AND recombinant surrogate cell containing an enhanced transcriptional control unit based on the primary late adenovirus coefficient
FR2671973A1 (fr) * 1991-01-25 1992-07-31 Fondation Nale Transfusion San Utilisation de la proteine c activee comme agent anti-agregant plaquettaire.
WO1993009807A1 (en) * 1991-11-18 1993-05-27 The Scripps Research Institute Methods of inhibiting thrombosis via elevation of circulating endogenous activated protein c levels
JPH05271098A (ja) * 1992-03-26 1993-10-19 Teijin Ltd 活性化プロテインｃを有効成分とする抗血小板剤
MY110664A (en) * 1992-05-21 1999-01-30 Lilly Co Eli Protein c derivatives
IL110172A (en) * 1993-07-22 2001-10-31 Lilly Co Eli Bicycle compounds and pharmaceuticals containing them
WO1997020043A1 (en) * 1995-11-30 1997-06-05 Zymogenetics, Inc. Protein c production in transgenic animals

Also Published As

Publication number Publication date
PL337223A1 (en) 2000-08-14
TR199903020T2 (xx) 2000-08-21
EP0882453A2 (en) 1998-12-09
PT882453E (pt) 2005-04-29
TWI228042B (en) 2005-02-21
DE69828462T2 (de) 2005-12-15
NO995776L (no) 2000-01-26
CN1265598A (zh) 2000-09-06
US6071514A (en) 2000-06-06
DK0882453T3 (da) 2005-05-09
JP2002502421A (ja) 2002-01-22
CN1347734A (zh) 2002-05-08
EP0882453A3 (en) 2001-04-04
AU7710098A (en) 1998-12-21
KR20010013413A (ko) 2001-02-26
ID23908A (id) 2000-05-25
ES2235291T3 (es) 2005-07-01
AU741983B2 (en) 2001-12-13
HUP0003964A2 (en) 2001-03-28
DE69828462D1 (de) 2005-02-10
ATE286404T1 (de) 2005-01-15
ZA984698B (en) 2000-02-01
WO1998055142A1 (en) 1998-12-10
CA2293429A1 (en) 1998-12-10
EP0882453B1 (en) 2005-01-05
BR9809932A (pt) 2000-08-01
NO995776D0 (no) 1999-11-25
EA199901112A1 (ru) 2000-06-26

Similar Documents

Publication Publication Date Title
SI0882453T1 (en) Use of APC in combination with an antiplatelet agent for treating thrombotic disorders
WO2000038665A3 (en) Use of an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
GB0403018D0 (en) Improved hand-held laser device for skin treatment
MY125564A (en) Combination therapy for treatment of psychoses
HUP9802093A3 (en) Use of nitrogen-monoxyde for producing medicament useful for treatment of vascular thrombosis and restenosis
PL349149A1 (en) Combination therapy of radiation and a cox-2 inhibitor for the treatment of neoplasia
HK1054389A1 (en) Quinoline and quinazoline compounds useful in therapy, particularly in the treatment of begnin prostatic hyperplasia.
EP1767197A3 (en) Treatment of Alzheimer's disease with inhibitors of cell cycle re-entry and progression
SE9404196D0 (sv) New antithrombotic formulation
ATE218854T1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin- abhängigen protein kinase
IL109802A0 (en) Pharmaceutical agents for treatment of emesis
BR0010531A (pt) Composições e usos de et743 para tratamento de câncer
HK1037980A1 (en) Use of selegiline or desmethylselegiline for the manufacture of a medicament for treating wounds, burns or photodamage.
MY118986A (en) Use of (alpha)-1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
DE60037032D1 (de) Anwendung von pdt zur inhibierung von hyperplasie der intima
NO308856B1 (no) Dermatansulfater og salter av disse
HUP0002836A2 (hu) Makrociklusos bisz(3,3'-indolil)-maleinimid-származékok alkalmazása bőrrendellenességek kezelésére szolgáló gyógyszerkészítmények előállítására
ATE141789T1 (de) Zusammensetzung enthaltend dibucaine- hydrochlorid, ein salicylat, calciumbromid und ein antiphlogistisches steroid zur schmerzbekämpfung
CA2297984A1 (en) Ratite extracts as therapeutic agents
DK664188D0 (da) Butylhydroxyanisoler til behandling af retrovirale sygdomme
NO984196D0 (no) Fremgangsmåte for behandling av stoffmisbruk
ATE314073T1 (de) Kombination von aktiva mit alfuzosin und apomorphin